Hepatitis B PBMC
About: Hepatitis B PBMC samples are collected from clinically confirmed Hepatitis B donors and cryopreserved. These PBMCs are ideal for T cell response, immune exhaustion, and cytokine production studies.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73142 | Hepatitis B | 10M | Caucasian | 73 | Female | United States (US) |
Xeralto 20mg QD Synthroid/0.5mg/QD Multivitamin/QD Calcium/QD Vitamin D/QD
|
2 | $765.00 | |
| 62541 | Hepatitis B | 10M | Caucasian | 73 | Female | United States (US) |
Xeralto 20mg QD Synthroid/0.5mg/QD Multivitamin/QD Calcium/QD Vitamin D/QD
|
4 | $765.00 | |
| 61949 | Hepatitis B | 10M | Caucasian | 73 | Female | United States (US) |
Xeralto 20mg QD Synthroid/0.5mg/QD Multivitamin/QD Calcium/QD Vitamin D/QD
|
4 | $765.00 | |
| 60656 | Hepatitis B | 50M | Caucasian | 41 | Female | United States (US) | 62 | $1,208.00 | ||
| 60741 | Hepatitis B | 10M | Caucasian | 54 | Female | United States (US) | 2 | $765.00 | ||
| 60436 | Hepatitis B | 10M | Caucasian | 73 | Female | United States (US) |
Xeralto 20mg QD Synthroid/0.5mg/QD Multivitamin/QD Calcium/QD Vitamin D/QD
|
7 | $765.00 | |
| 53534 | Hepatitis B | 10M | Caucasian | 72 | Female | United States (US) |
Entecavir/0.5mg/QD Albuterol Inhaler/PRN Fosamax 70 mg po QW
|
5 | $765.00 | |
| 51450 | Hepatitis B | 10M | Caucasian | 49 | Female | United States (US) |
Hydroxyzine QD PRN Diclofenac Sodium 1% Gel topically QID Glucosamine HCL 1,500 mg po QD Trileptal 300 mg po PRN Imitrex 100 mg Q2H PRN Lidocaine cream PRN
|
2 | $765.00 | |
| 50082 | Hepatitis B | 10M | Asian/Pacific Islander | 37 | Female | United States (US) |
Tenofovir/300mg/QD
|
3 | $765.00 | |
| 53661 | Hepatitis B | 10M | Asian/Pacific Islander | 43 | Male | United States (US) |
Tenofovir/300mg/QD
|
4 | $765.00 |
High-Quality Hepatitis B PBMC for Research
Hepatitis B Human PBMC products are sourced from donors clinically diagnosed with Hepatitis B and processed under stringent conditions to support immunology research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on T cell responses, immune exhaustion, and cytokine production.
Product Features
- Research Use Only (RUO), cryopreserved PBMC
- Clinically confirmed Hepatitis B donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified Hepatitis B diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional Hepatitis B-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in Hepatitis B pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Hepatitis B PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Hepatitis B Publications
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.